Lung Malignancies in HIV Infection.

Area of Science:

• Oncology
• Infectious Diseases
• Pulmonology

Background:

• Pulmonary malignancies represent a significant cause of illness and death in individuals with HIV.
• Non-AIDS-defining lung cancers, primarily non-small cell lung cancers, are a leading cause of cancer mortality in the HIV-infected population.
• HIV-associated factors influence lung cancer risk and may negatively affect treatment outcomes.

Purpose of the Study:

• To examine the impact of HIV infection on lung cancer risk, treatment, and screening.
• To understand the changing landscape of AIDS-defining versus non-AIDS-defining lung malignancies in the context of antiretroviral therapy.

Main Methods:

• Review of existing literature and data on lung cancer incidence and outcomes in HIV-infected individuals.
• Analysis of how HIV-specific factors modulate lung cancer development and response to therapy.
• Evaluation of the implications of HIV on computed tomography (CT) screening for lung cancer.

Main Results:

• Non-AIDS-defining lung cancers are now a primary cause of cancer death among people with HIV.
• HIV infection can alter lung cancer risk and complicate treatment and outcomes.
• The benefits and risks of lung cancer screening via CT may be modified by HIV status.
• Pulmonary Kaposi sarcoma and lymphoma, once common AIDS-defining lung cancers, are now less prevalent due to effective antiretroviral therapy.

Conclusions:

• HIV-infected individuals face a significant burden of non-AIDS-defining lung cancers.
• Understanding HIV's role is crucial for optimizing lung cancer management, including screening and treatment, in this population.
• Antiretroviral therapy has successfully reduced the incidence of AIDS-defining pulmonary malignancies.